Wellpharma Medical Solutions (WMS) is the UAE’s first and IV solutions manufacturing plant to cater to the ever-growing demand of life saving IV solutions in DEHP free containers in bags. WMS is the project of Infra Capital Investments (Infra Capital), a conglomerate in the field of Investment opportunities and situated at Industrial City of Abu Dhabi (ICAD), Musaffah.
Who We Are
Who We Are
UAE’s First & IV Solutions Manufacturing Plant
- Spread over an area of 7500sqm.
- WMS is an ultramodern & state of the art facility.
- Equipped with latest technology and top-class equipment’s.
- Constructed in technical collaboration with Bram Spa Italy.
- The facility complies with the latest USFDA, EU and ISPE standards.
Production Capacity
For catering to the needs of society and healthcare system, WMS has divided its plan in three stages.
This approach allows for a systematic and organized expansion of their operations while ensuring a steady supply of life-saving IV solutions. The staged plan enables WMS to gradually increase production capacity, enhance technological capabilities, and respond to the evolving demands of the market.
- Mass production of life saving IV fluids (50ml to 1000ml bags)
- Mass production of Large Volume Parenteral (LVP’s) – 3L/5L
- Kidney Dialysis
- Water for Irrigation
- Therapeutic Products
Quality Management Systems
Wellpharma complies to cGMP standards and adheres to stringent Quality Management Systems.
Quality Assurance System
Controlling all stages from sourcing to dispatching to the market
Continuous Improvement
In quality and compliance of processes and products from development to distribution
Focus on Patient Safety
Data integrity and fulfillment of customer expectations
We invest in quality you can trust
WellPharma’s Quality Control Lab is fully equipped with the latest technologies for chemical & microbiological testing.
WellPharma is pursuing an active growth strategy to accelerate healthy outcomes across MENA.
Entering new markets:
- Enabling regional expansion in GCC, Levant, and Nort Africa.
- Developing new product ranges.
- Developing new formulations in the general IV fluid, ophthalmic, and renal disease therapeutic areas.
Stay Connected
Connect with us on LinkedIn for the latest updates and professional insights.
All rights reserved © 2023 Wellpharma. Powered by Ibtikar Edu Tech Solutions